Heart Failure With Preserved Ejection Fraction (HFpEF)

Cardiovascular
4
Pipeline Programs
4
Companies
17
Clinical Trials
3 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
DAPAGLIFLOZINApproved
dapagliflozin
Unknown Company
AstraZeneca
FARXIGAApproved
dapagliflozin
AstraZeneca
oral2014

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
1
1
1
FARXIGA(Dapagliflozin)Phase 3Small Molecule1 trial
AZD4831Phase 15 trials
Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas N/A1 trial
Active Trials
NCT07185100Recruiting450Est. Dec 2035
NCT05492877Completed381Est. Aug 2024
NCT05638737Completed112Est. Apr 2024
+4 more trials
Verona Pharma
Verona PharmaUK - London
1 program
Aerobic eccentric interventionN/A1 trial
Active Trials
NCT06826963Recruiting15Est. Sep 2025
Abbott
AbbottABBOTT PARK, IL
1 program
ILR implantationN/A1 trial
Active Trials
NCT01989299Completed113Est. Jun 2020
Rhythm Pharmaceuticals
1 program
Personalized cardiac pacingN/A1 trial
Active Trials
NCT06678841Recruiting700Est. Feb 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstraZenecaDapagliflozin
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaAZD4831
AstraZenecaDetermination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas
Rhythm PharmaceuticalsPersonalized cardiac pacing

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 3,294 patients across 17 trials

NCT03877224AstraZenecaDapagliflozin

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Start: Apr 2019Est. completion: Jul 2020504 patients
Phase 3Completed
NCT04986202AstraZenecaAZD4831

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Start: Jun 2021Est. completion: Mar 2024711 patients
Phase 2/3Completed
NCT05492877AstraZenecaAZD4831

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

Start: Nov 2022Est. completion: Aug 2024381 patients
Phase 2Completed
NCT05638737AstraZenecaAZD4831

A Study in Participants With Non-cirrhotic NASH With Fibrosis

Start: Oct 2022Est. completion: Apr 2024112 patients
Phase 2Completed
NCT03756285AstraZenecaAZD4831

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

Start: Dec 2018Est. completion: May 202041 patients
Phase 2Terminated
NCT05457270AstraZenecaAZD4831

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Start: Aug 2022Est. completion: Oct 202230 patients
Phase 1Completed
NCT05236543AstraZenecaAZD4831

A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole

Start: Feb 2022Est. completion: Aug 202221 patients
Phase 1Completed
NCT04949438AstraZenecaAZD4831

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Start: Jan 2022Est. completion: Mar 202220 patients
Phase 1Completed
NCT05052710AstraZenecaAZD4831

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Start: Oct 2021Est. completion: Nov 202114 patients
Phase 1Completed
NCT04407091AstraZenecaAZD4831

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Start: Jun 2020Est. completion: Aug 20208 patients
Phase 1Completed
NCT04232345AstraZenecaAZD4831

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Start: Jan 2020Est. completion: Mar 202132 patients
Phase 1Completed
NCT03136991AstraZenecaAZD4831

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Start: May 2017Est. completion: Nov 201738 patients
Phase 1Completed
NCT02712372AstraZenecaAZD4831

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Start: Jun 2016Est. completion: Oct 2016104 patients
Phase 1Terminated
NCT07185100AstraZenecaDetermination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Start: Sep 2025Est. completion: Dec 2035450 patients
N/ARecruiting
NCT06678841Rhythm PharmaceuticalsPersonalized cardiac pacing

ELEVATE-HFpEF Clinical Study

Start: Jul 2025Est. completion: Feb 2029700 patients
N/ARecruiting
NCT06826963Verona PharmaAerobic eccentric intervention

Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study

Start: Oct 2024Est. completion: Sep 202515 patients
N/ARecruiting
NCT01989299AbbottILR implantation

Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction

Start: Nov 2014Est. completion: Jun 2020113 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr

Physician Program Director, Los Angeles

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

J&J MedTech Neurovascular Senior Financial Analyst, R&D

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$79K - $128K/yr

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 3,294 patients
4 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)